Experience
Andrx Pharmaceuticals
Elan Corporation PLC
Andrx Pharmaceuticals, Inc. (“Andrx”) filed suit against Finnegan client Elan Corporation PLC, alleging that Elan violated the federal antitrust Sherman Act and various Florida antitrust statutes by entering into a settlement agreement in an Abbreviated New Drug Application (“ANDA”) patent infringement litigation that Elan brought against another company, and by initiating an ANDA litigation against Andrx relating to the same patent. Finnegan obtained judgment on the pleadings in Elan’s favor on all issues at the outset of the case. The U.S. Court of Appeals for the Eleventh Circuit affirmed the majority of the holdings, including that the Noerr-Pennington doctrine shielded Elan from Andrx’s patent misuse claims relating to Elan’s assertion of its patent against Andrx. The Eleventh Circuit remanded the settlement agreement holding for further proceedings. Andrx ultimately agreed to dismiss the claim.
Andrx Pharmaceuticals v. Elan Corporation PLC, 03-13605, 11th Cir., Judges Birch, Dowd, Wilson
Elan Corporation PLC v. Andrx Pharmaceuticals, 1:00-cv-03481, S.D. Fla., Judge Jordan
GlaxoSmithKline
A high-impact result for R&D licensing programs in the pharmaceutical industry
Elan Corporation PLC
Toyota Motor Corp.
District court enters judgment of noninfringement for Finnegan client Philips
Koninklijke Philips Electronics N.V.
Philips protected against antitrust and misuse charges in DVD and CD infringement litigation
U.S. Philips Corp.
Elan Pharmaceuticals, Inc. v. Eon Labs, Inc.
Elan Pharmaceuticals, Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.